DHODH-IN-14 is an analog of hydroxyfuran pyrimidine A771726. DHODH-IN-14 is a dihydroorotate dehydrogenase (DHODH) inhibitor IC50 0.49 μM mouse liver DHODH. DHODH-IN-14 can be used for rheumatoid arthritis.

DHODH-IN-1 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor with IC50 of 25 nM. DHODH-IN-1 is an inhibitor of the pyrimidine biosynthetic pathway.

DHODH-IN-4 is a human and Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) inhibitor. The IC50 values of PfDHODH and HsDHODH are 4 μM and 0.18 μM, respectively. DHODH-IN-4 has antimalarial activity.

hDHODH-IN-5 is an inhibitor of human dihydroorotate dehydrogenase (hDHODH, IC50 = 0.91 μM).

hDHODH-IN-7 (DHODH-IN-9) is a nitrogen-containing analog and is a human dihydrorotatory dehydrogenase inhibitor. hDHODH-IN-7 and pMIC50 of 7.4 have antiviral effects.

DHODH-IN-13 is an inhibitor of DHODH with IC50 of 4.3 μM for rat liver. DHODH-IN-13 can be used in studies about rheumatoid arthritis.

DHODH-IN-12 is a leflunomide derivative and a weak dihydrorotate dehydrogenase (DHODH) inhibitor with a pKa of 5.07.

DHODH-IN-15 is the hydroxyfuran analogue of A771726. DHODH-IN-15 is a dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 11 μM for rat liver DHODH. DHODH-IN-15 can be used for rheumatoid arthritis.

DHODH-IN-8 has antimalarial activity. DHODH-IN-8 is an inhibitor of human and Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) with IC50 of 0.13 μM and 47.4 μM, and Kis of 0.016 μM and 5.6 μM, respectively.

hDHODH-IN-3 is an inhibitor of human dihydroorotate dehydrogenase with a pMIC50 value of 8.6. hDHODH-IN-3 can inhibit measles virus replication.

hDHODH-IN-4 (DHODH-IN-5) is a potent inhibitor of human dihydrogen dehydrogenase (DHODH). For human recombinant DHODH, its pIC50 is 7.8. hDHODH-IN-4 inhibits measles virus replication with a pMIC50 of 8.8.

DHODH-IN-17 is a human DHODH inhibitor with an IC50 of 0.40 μM. DHODH-IN-17 is a 2- anilino nicotinic acid that can be used in the study of acute myeloid leukemia (AML).

DHODH-IN-23 is a DHODH inhibitor with oral activity. DHODH-IN-23 is often used in cancer research.

DHODH-IN-16 is an effective inhibitor of dihydroorotate dehydrogenase (DHODH, IC50 = 0.396 nM for human).

Dhodh-in-20 (Compound 133) is a potent inhibitor of DHODH. Among them, DHODH is an iron-containing flavin-dependent enzyme that is present in the inner membrane of human mitochondria. DHODH-IN-20 showed an inhibitory effect on tumor growth. DHODH-IN-20 has the potential to be used in the study of acute myeloid leukemia.

RORγt/DHODH-IN-3 (compound (S)-14d) is a potent, orally active dual inhibitor of RORγt (IC50: 0.098 μM) and DHODH (IC50: 0.432 μM).RORγt/DHODH-IN-1 has significant in vivo anti-inflammatory effects.

DHODH-IN-11 is a leflunomide derivative and weak dihydroorotate dehydrogenase (DHODH) inhibitor with a pKa of 5.03.

DHODH-IN-19 is a potent inhibitor of DHODH. DHODH-IN-19 has shown research potential for cancer and inflammatory diseases.

DHODH-IN-21 is an orally active, selective dihydrolactate dehydrogenase (DHODH) inhibitor (IC50: 1.1 nM). DHODH-IN-21 exhibits anticancer effects and can be used to study acute myeloid leukemia (AML).

RORγt/DHODH-IN-2 (compound 1) is a potent dual RORγt/DHODH inhibitor that can be used in the study of inflammatory bowel disease (IBD).

RORγt/DHODH-IN-1 (compound (R)-14d) is a potent, orally active dual inhibitor of RORγt (IC50: 0.083 μM) and DHODH (IC50: 0.172 μM), which exhibits significant in vivo anti-inflammatory effects.

DHODH-IN-18 is a human DHODH inhibitor ( IC 50 = 0.2 nM).

DHODH-IN-3 is an effective inhibitor of human dihydroorotate dehydrogenase (HsDHODH) with IC50 value of 261 nM. DHODH-IN-3 binds to the ubiquinone binding cavity in DHODH with a Kiapp of 32 nM. DHODH-IN-3 has the potential to treat malaria.

DHODH-IN-22 is a potent, selective, orally active inhibitor of dihydroorotic dehydrogenase (DHODH) (IC50: 0.3 nM) and can be used in acute myeloid leukaemia (AML) studies.

Olorofim is a novel selective antifungal compound with inhibitory effect on Aspergillus fumigatus DHODH (IC50: 44 nM) and almost no inhibitory effect on human DHODH (>100 uM).Olorofim has good efficacy against various pathogenic filamentous and dimorphic fungi such as Penicillium spp, Dermatophilus spp and Fusarium spp.

PfDHODH-IN-2 is a dihydrothiophenone derivative, is a potent Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH, IC50 : 1.11 μM) inhibitor . It is used an antimalarial agent and can be used for the research of malaria

hDHODH-IN-8 is a potent inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an IC50 of 16 nM. hDHODH-IN-8 has potent antiproliferative activity and excellent aqueous solubility. hDHODH-IN-8 has the potential for the research of tumor disease, especially lymphoma.

PfDHODH-IN-1 is an analogue of the active Leflunomide metabolite, has antimalarial activity.

hDHODH-IN-13 (compound w2), an inhibitor of human dihydroorotate dehydrogenase (hDHODH), exhibits an IC50 of 173.4 nM and has potential research applications in studying inflammatory bowel disease (IBD) [1].

DSM421 (DSM-421) is a dihydrodehydrogenase inhibitor (DHODH) that is in preclinical development as a potential treatment option for malaria and has shown activity against field isolates of both P. falciparum and P. vivax.

Orotic acid zinc (Zinc Orotate) salt dihydrate is an intermediate product in pyrimidine synthesis.

hDHODH-IN-12 is a potent inhibitor of dihydroorotate dehydrogenase (DHODH), exhibiting an inhibitory concentration (IC50) of 0.421 μM. As the rate-limiting enzyme in the de novo synthesis of pyrimidines, critical for DNA/RNA synthesis, DHODH is localized within the inner membrane of human mitochondria. hDHODH-IN-12 is applicable in lung cancer research [1].

hDHODH-IN-9 (Compound 3k) is a highly potent inhibitor of hDHODH, exhibiting an IC50 of 0.34 μM. It displays significant cytotoxic activity against MCF-7 and A375 cells, while maintaining good selectivity. With its characteristics, hDHODH-IN-9 holds promise for cancer disease research [1].

hDHODH-IN-2 is an analogue of the active metabolite of Leflunomide. hDHODH-IN-2 is a human dihydroorotate dehydrogenase (hDHODH) inhibitor with anti-inflammatory activity.

hDHODH-IN-11, a potent inhibitor of human dihydroorotate dehydrogenase (hDHODH), exhibits an IC50 value of 7.2 nM and has low cytotoxicity. It is applicable in acute myeloid leukemia (AML) research.

hDHODH-IN-10 is a selective, orally active, potent hDHODH inhibitor (IC50: 10.9 nM) that forms hydrogen bonds with key residues Arg136 and Gln47. hDHODH-IN-10 inhibits the proliferation of cancer cells and can be used to study cancers (e.g. AML, colon cancer).

hDHODH-IN-1 is a human dihydroorotate dehydrogenase (hDHODH) inhibitor with an anti-inflammatory effect.

Vidofludimus (SC12267) (4SC-101, SC12267) is a novel small molecule inhibitor of dihydroorotate dehydrogenase (DHODH).

Brequinar (NSC-368390) is a potent inhibitor of dihydroorotate dehydrogenase, with potent activities against a broad spectrum of viruses.

AG-636 is a potent, reversible, selective and orally active DHODH inhibitor(IC50 of 17 nM). It has strong anticancer effects.

Laflunimus suppresses immunoglobulin (Ig) secretion, with IC50 values of 2.5 and 2 μM for IgM and IgG, respectively. Laflunimus also is a prostaglandin endoperoxide H synthase (PGHS) -1 and -2 inhibitor. Laflunimus is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of dihydroorotate dehydrogenase (DHODH).

GSK983, a potent broad-spectrum antiviral, blocks cell proliferation and dengue virus replication by inhibiting the pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase (DHODH).

Tenovin-6 Hydrochloride is an SIRT1, SIRT2 and HDAC8 inhibitor(IC50s of 21 μM, 10 μM, and 67 μM for SirT1, SirT2, and SirT3, respectively), and is also a potent p53 activator .

BRD9185 is an inhibitor of Dihydroorotate dehydrogenase (DHODH) with an EC50 of 16 nM against multidrug-resistant blood-stage parasites in vitro.

ML390 exerts its potent differentiation effect on multiple leukemia models.

DSM705 is a pyrrole-based inhibitor of Dihydroorotate Dehydrogenase (DHODH). It demonstrates high potency in the nanomolar range against Plasmodium DHODH and Plasmodium parasites, while not interfering with mammalian DHODHs. DSM705 shows significant efficacy as an antimalarial compound.

Vidofludimus hemicalcium (4sc-101; SC12267) is an orally active compound that acts as a dihydroorotate dehydrogenase (DHODH) inhibitor and serves as a novel modulator of the farnesoid X receptor (FXR). This immunomodulatory agent is utilized in the research of autoimmune disorders, including inflammatory bowel disease (IBD), and is explored for its potential in fatty liver disease research through FXR targeting.

Indoluidin E selectively inhibits DHODH and has an inhibitory effect on cancer cell growth.

(E/Z)-Ginkgolic acid C17:2 (Ginkgolic Acid C17:2) is a natural product that can be extracted from Ginkgo biloba and targets human dihydroorotic acid dehydrogenase (DHODH).

Tenovin-1 inhibits protein-deacetylating activities of SirT1 and SirT2 and protects against MDM2-mediated p53 degradation, which involves ubiquitination.